跳至主要内容
临床试验/PACTR201609001765772
PACTR201609001765772已完成未知

The Clinical Outcome of the Combination Regimen of Ginkgo biloba Extract with Ursodeoxycholic acid in Chronic Hepatitis C Egyptian Patients

Dina Mohamed kamal El-Gindy0 个研究点目标入组 67 人开始时间: 2016年9月5日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
67

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Year(s) 至 65 Year(s)(—)
性别
All

入选标准

  • positive serum anti-HCV Ab and HCV RNA
  • clinical and ultrasonographic criteria suggestive of chronic hepatitis C
  • Elevation of ALT at least 1.5 times the upper limit of normal (but < 5 times the normal limit)
  • Child Pugh Grade A

排除标准

  • Child Pugh Grade was B or C
  • had other causes of liver disease or had evidence of advanced liver disease e.g. history or presence of ascitis, bleeding esophageal varices, or hepatic encephalopathy.
  • had portal vein thrombosis, hepatocellular carcinoma, seizure disorders
  • body mass index >40
  • advanced systemic disease like heart failure or any debilitating disease that will affect life expectancy
  • using oral contraceptive pills, selective serotonin reuptake inhibitors, narcotic drugs, blood thinning drugs or those who received a treatment of antiviral agents (interferon with or without ribavirin) in the previous 2 months.
  • pregnancy or lactation
  • patients with platelet level <50,000/µL patients with sensitivity to UDCA or EGb.

研究者

发起方
Dina Mohamed kamal El-Gindy

相似试验